Cardiac risk management among vascular surgery patients has undergone major transitions in the last 20 years. Specifically, evaluation and treatment have gradually changed from a very invasive approach to a non-invasive one. In the early 1980s, Hertzer and colleagues at the Cleveland Clinic were the first to elucidate the strong relationship between severe coronary artery disease and peripheral arterial disease in patients about to undergo vascular surgery. 1 Based on their experience, it was clinically justifiable at the time to consider coronary angiography on all patients undergoing peripheral arterial surgery, followed by coronary revascularization for significant lesions.
A more conservative approach was forged when Goldman, Eagle and co-workers, and others were able to show that vascular surgery risk can be elegantly stratified using discrete, established, clinical risk factors. 2, 3 Simultaneous with the advent of risk stratification came dipyridamole/thallium imaging and similar modalities that do not require exercise, which were shown to be of value in identifying high-risk vascular surgery patients. 4 Hence, in the late 1980s, risk stratification followed by dipyridamole/thallium imaging became the standard of care in evaluating patients about to undergo vascular surgery, with high-risk patients being referred for preoperative coronary angiography and revascularization.
Three developments have emerged that may once again move the management of vascular surgery patients towards a simpler, more streamlined approach. First, the cardiac risk of patients undergoing vascular surgery has been decreasing, largely thanks to the heightened attention and closer monitoring afforded these patients. Secondly, more recent data suggest that dipyridamole/thallium imaging and similar modalities, when used as screening tools, may not be as useful as initially thought. 5 Lastly, Mangano and co-workers and Poldermans and co-workers have shown that beta-blocker therapy in the perioperative period will safeguard high-risk general surgery patients as well as patients undergoing vascular procedures. 6, 7 These landmark studies validate new and old reports that have advocated the wider use of perioperative beta blockade in high-risk vascular surgery patients, 8, 9 and advocate beta blockade as the definitive therapy for perioperative risk reduction. If beta-blocker therapy is to replace a more invasive and complex approach of cardiac risk management, is preoperative cardiac testing necessary among vascular surgery patients?
The article by Krupski and co-workers published in this Vascular Medicine issue provocatively asks the same question. 10 This group studied 42 patients scheduled to undergo major vascular operations in the mid-1990s and followed them for the consequences of an extended cardiac evaluation that was ordered by the managing surgeons, cardiolo-gists, and anesthesiologists. No definite protocol was followed. However, data were kept on the cardiac history, the available laboratory, electrocardiographic, and imaging data obtained preoperatively. Careful follow-up was made of the consequences of coronary angiography as well as coronary revascularization therapy. The authors were able to show that a cardiac evaluation comparable with that espoused by most clinicians resulted in significant cost, morbidity and mortality in this patient group. In addition, a substantial number of patients (19%) refused vascular surgery after their extended cardiac work-up. Complications included prosthetic graft infection, pseudoaneurysms, sternal wound infections, renal failure, and brain anoxia: events that are often under-reported in efficacy trials of coronary bypass surgery and PTCA. The authors also documented two cases of amputations in what otherwise might have been successful revascularization therapy were it not for the delay built in by cardiac evaluation.
Coupled with recent data that offers beta-blocker therapy as a realistic and practical approach to high-risk patients with coronary artery disease about to undergo vascular surgery, the data presented by Krupski and co-workers is food for thought about the overall approach to this patient population. Trials that have advocated prophylactic coronary revascularization therapy for patients undergoing vascular surgery have failed to document the consequences of coronary angiography and revascularization therapy prior to proceeding with vascular surgery. When Krupski and coworkers take this into account, they successfully call into question the efficacy of extensive cardiac evaluations and coronary revascularization therapy as prophylactic maneuvers.
The current study has its limitations. It has small numbers and is not a randomized controlled trial. The absence of a definitive protocol for the approach to these patients makes the data hard to interpret. As the authors point out, the high rate of morbidity experienced by the study group may in fact be because these patients were selected by the cardiac evaluation as being more likely to experience adverse outcomes. Furthermore, the authors cannot take into account the potential long-term benefits of coronary revascularization. But Krupski and co-workers' data support the argument that coronary angiography and revascularization should only be undertaken if they are indicated for factors independent of the vascular surgery that these patients undergo. Moreover, definitive randomized studies are now available that suggest that high-risk vascular surgery patients who do not have an independent indication for coronary revascularization do better with perioperative beta blockade than with risk stratification, preoperative stress imaging, and risk-guided interventions.
Is preoperative cardiac testing necessary among vascular surgery patients? Based on the above body of evidence, the answer for most patients appears to be: No.
